The management of diffuse large B-cell lymphoma

被引:0
作者
Liapis, K. [1 ]
Karmiris, T. [1 ]
机构
[1] Evangelismos Gen Hosp, Dept Hematol & Lymphoma, 45-47 Ipsilantou St, GR-10676 Athens, Greece
来源
ARCHIVES OF HELLENIC MEDICINE | 2010年 / 27卷 / 01期
关键词
Aggressive lymphoma; Diffuse large B-cell lymphoma; Immunochemotherapy;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diffuse large B-cell lymphoma (DLBCL) is the most common histologic type among the lymphomas. It is an aggressive neoplasm but also constitutes a therapeutic challenge since in many cases it can be cured, due to its inherent chemosensitivity. The biology and the clinical course of DLBCL are highly heterogenous and efforts have been made to identify clinical risk factors in order to apply a stratification system. A plethora of chemotherapeutic combinations have been used to treat DLBCL, but the CHOP regimen remains the treatment of choice for the majority of patients. The addition of rituximab to CHOP (immunochemotherapy) represents a significant step forward, and this has been widely accepted as the standard combination. Many questions, however, are still unanswered, and for many patients the outcome of treatment falls short of expectations. This paper provides a comprehensive review of the prognosis of primary nodal DLBCL and its first-line treatment.
引用
收藏
页码:48 / 65
页数:18
相关论文
共 95 条
[1]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[2]   Epidemiology of the non-Hodgkin's lymphomas: Distributions of the major subtypes differ by geographic locations [J].
Anderson, JR ;
Armitage, JO ;
Weisenburger, DD .
ANNALS OF ONCOLOGY, 1998, 9 (07) :717-720
[3]   How I treat patients with diffuse large B-cell lymphorna [J].
Armitage, James O. .
BLOOD, 2007, 110 (01) :29-36
[4]   ADJUVANT RADIOTHERAPY TO SITES OF PREVIOUS BULKY DISEASE IN PATIENTS STAGE-IV DIFFUSE LARGE-CELL LYMPHOMA [J].
AVILES, A ;
DELGADO, S ;
NAMBO, MJ ;
ALATRISTE, S ;
DIAZMAQUEO, JC .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 30 (04) :799-803
[5]  
Barosi G, 2006, HAEMATOLOGICA, V91, P96
[6]  
Bartlett NL, 2001, CANCER, V92, P207, DOI 10.1002/1097-0142(20010715)92:2<207::AID-CNCR1311>3.0.CO
[7]  
2-D
[8]  
BONNET C, 2002, ANN ONCOL, V13, P27
[9]   For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? [J].
Bos, GMJ ;
van Putten, WLJ ;
van der Holt, B ;
van den Bent, M ;
Verdonck, LF ;
Hagenbeek, A .
ANNALS OF ONCOLOGY, 1998, 9 (02) :191-194
[10]  
CHEN MG, 1979, CANCER, V43, P1245, DOI 10.1002/1097-0142(197904)43:4<1245::AID-CNCR2820430412>3.0.CO